Attovia Closes $105 Million Series B

<p><strong>FREMONT<&sol;strong> &&num;8212&semi; Attovia Therapeutics has closed a &dollar;105 million oversubscribed Series B financing&comma; bringing the total capital raised by the Company since its launch in June 2023 to &dollar;165 million&period; Proceeds from the financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts&comma; expand the Company’s immunology and inflammation pipeline&comma; and to further develop the ATTOBODY platform&period;<&sol;p>&NewLine;<p>The Series B financing was led by Goldman Sachs Alternatives&comma; with participation from new investors Cormorant Asset Management&comma; Nextech Ventures&comma; Redmile Group&comma; EcoR1 Capital&comma; Marshall Wace&comma; and Logos Capital&period; Attovia’s existing investors Frazier Life Sciences&comma; venBio&comma; and Illumina Ventures&comma; also participated in the round&period; Concurrent with the financing&comma; Colin Walsh&comma; Ph&period;D&period;&comma; Managing Director within Life Sciences Investing at Goldman Sachs Alternatives&comma; was appointed to the Company’s Board of Directors&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The strong investor interest and timing of this financing underscore the rapid progress we made with Attovia’s differentiated pipeline since the company inception&comma; and the unique potential of our proprietary platform to develop attractive&comma; next-generation immunology product candidates&comma;” said Tao Fu&comma; chief executive officer of Attovia&period; &OpenCurlyDoubleQuote;We are grateful for the support from such a strong group of investors&comma; allowing us to advance our lead programs to the clinic in the near term&comma; further expand our pipeline in novel bi-specifics&comma; and catalyze potential business development opportunities&period;”<&sol;p>&NewLine;<p>Attovia is advancing a pipeline of spatially optimized biparatopic biologics generated from its ATTOBODY™ platform&period; The Company’s lead programs&comma; ATTO-1310&comma; a potential first-in-class&comma; long half-life anti-IL31 ATTOBODY&comma; and ATTO-002&comma; a bispecific anti-IL31 x IL13 ATTOBODY&comma; represent potential best-in-class therapeutics for a range of immune-mediated diseases&period; ATTO-1310 is currently in IND enabling studies and is on track to enter the clinic around year-end 2024 for the treatment of atopic dermatitis and other pruritic diseases&period; Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025&period; The Company is also developing discovery stage programs that expand the ATTOBODY platform footprint to novel&comma; difficult-to-drug targets&comma; and offer additional multi-specific combinations&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We believe Attovia is well positioned to be a leader in the development of best-in-class novel biologics for patients suffering from a range of diseases in immunology and inflammation&comma;” said Colin Walsh&comma; Managing Director within Life Sciences Investing at Goldman Sachs Alternatives&period; &OpenCurlyDoubleQuote;In a short amount of time&comma; Attovia has leveraged its ATTOBODY platform to generate an impressive pipeline&comma; and we are thrilled to support the further buildout of the company at this pivotal stage&period;”<&sol;p>&NewLine;